Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis

Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis

Abstract Background B cells are critical mediators of systemic lupus erythematosus (SLE) and lupus nephritis (LN), and antinuclear antibodies can be found in the serum of approximately 98% of patients with SLE. Spleen tyrosine kinase (SYK) is a nonreceptor tyrosine kinase that mediates signaling fro...

Full description

Bibliographic Details
Main Authors: Christopher W. Pohlmeyer, Ching Shang, Pei Han, Zhi-Hua Cui, Randall M. Jones, Astrid S. Clarke, Bernard P. Murray, David A. Lopez, David W. Newstrom, M. David Inzunza, Franziska G. Matzkies, Kevin S. Currie, Julie A. Di Paolo
Format: Article
Language:English
Published: BMC 2021-03-01
Series:BMC Rheumatology
Subjects:
Spleen tyrosine kinase
SYK inhibition
B-cell receptor
B-cell signaling
Immunohistochemistry
Systemic lupus erythematosus
Online Access:https://doi.org/10.1186/s41927-021-00178-3

Internet

https://doi.org/10.1186/s41927-021-00178-3

Similar Items